PMID- 34972971
OWN - NLM
STAT- MEDLINE
DCOM- 20220104
LR  - 20220531
IS  - 0065-2598 (Print)
IS  - 0065-2598 (Linking)
VI  - 1342
DP  - 2021
TI  - Skin Reactions to Immune Checkpoint Inhibitors.
PG  - 319-330
LID - 10.1007/978-3-030-79308-1_11 [doi]
AB  - Due to the novelty of immune checkpoint inhibitors, their cutaneous adverse 
      events (AEs) have only been recently characterized. This, along with the 
      substantial rate of cutaneous reactions, has left many clinicians without 
      sufficient familiarity to diagnose and treat cutaneous AEs. Pruritus and rash are 
      among the top five immune-related AEs reported in clinical trials for this class 
      of therapy. Incidence varies between 35 and 60% for cutaneous AEs among the seven 
      FDA-approved drugs used as monotherapy or combination therapy. Although only 2% 
      are reported as grade 3 or 4 events with monotherapy, the incidence can be as 
      high as 6-9% for combination therapy and the impact on quality of life can be 
      significant for these patients. Of ipilimumab patients, 43.5% have a cutaneous 
      AE, and, at our institution, 20% of them had a dose interruption as a result. 
      This means potentially 9% of patients have dose interruption of ipilimumab 
      because of their cutaneous AEs. In the following chapter, we review the 
      categories of these drugs, common cutaneous effects, their grading, and 
      management options.
CI  - (c) 2021. The Author(s), under exclusive license to Springer Nature Switzerland AG.
FAU - Patel, Anisha B
AU  - Patel AB
AD  - Department of Dermatology, The University of Texas MD Anderson Cancer Center, 
      Houston, TX, USA. APatel11@mdanderson.org.
FAU - Pacha, Omar
AU  - Pacha O
AD  - Department of Dermatology, The University of Texas MD Anderson Cancer Center, 
      Houston, TX, USA.
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United States
TA  - Adv Exp Med Biol
JT  - Advances in experimental medicine and biology
JID - 0121103
RN  - 0 (Immune Checkpoint Inhibitors)
RN  - 0 (Ipilimumab)
SB  - IM
MH  - *Exanthema/chemically induced
MH  - Humans
MH  - *Immune Checkpoint Inhibitors/adverse effects
MH  - Ipilimumab/adverse effects
MH  - Quality of Life
OTO - NOTNLM
OT  - Anti-CTLA-4
OT  - Dermatitis
OT  - Immune checkpoint inhibitors
OT  - Immunotherapy
OT  - Ipilimumab
OT  - Nivolumab Anti-PD-1
OT  - Pruritus
OT  - Rash
EDAT- 2022/01/02 06:00
MHDA- 2022/01/05 06:00
CRDT- 2022/01/01 05:27
PHST- 2022/01/01 05:27 [entrez]
PHST- 2022/01/02 06:00 [pubmed]
PHST- 2022/01/05 06:00 [medline]
AID - 10.1007/978-3-030-79308-1_11 [doi]
PST - ppublish
SO  - Adv Exp Med Biol. 2021;1342:319-330. doi: 10.1007/978-3-030-79308-1_11.